Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03019003 |
|
Recruitment Status :
Active, not recruiting
First Posted : January 12, 2017
Last Update Posted : February 21, 2023
|
Sponsor:
Massachusetts General Hospital
Collaborators:
AstraZeneca
Astex Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Sara Pai, MD, PhD, Massachusetts General Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | July 2023 |
| Estimated Study Completion Date : | January 2025 |